论文部分内容阅读
目的观察咪喹莫特联合伐昔洛韦治疗首诊为生殖器疱疹的临床疗效。方法 120例首诊为生殖器疱疹患者随机分成联合组60例和对照组60例,其中联合组外用5%咪喹莫特乳膏,3次/周,共8周,口服伐昔洛韦片0.3g,2次/d,共10d;对照组仅口服伐昔洛韦片,用法同治疗组;两组均于初始治疗后12周和24周观察生殖器疱疹的复发情况。结果 12周时,联合组复发率(16.67%)明显低于对照组(36.71%),两组差异有统计学意义(P<0.05);第24周时,两组复发率差异无统计学意义。结论联合外用咪喹莫特在发病初期可减少首诊为生殖器疱疹的复发,但远期疗效不显著。
Objective To observe the clinical efficacy of imiquimod combined with valacyclovir in the treatment of genital herpes. Methods One hundred and twenty first cases of genital herpes were randomly divided into 60 cases in combination group and 60 cases in control group. The combination group was treated with 5% imiquimod cream 3 times a week for 8 weeks. g twice a day for 10 days. The control group was given oral valacyclovir tablets only. The treatment group was treated with the same method. The recurrence of genital herpes was observed in both groups at 12 weeks and 24 weeks after initial treatment. Results The recurrence rate (16.67%) in the combined group was significantly lower than that in the control group (36.71%) at 12 weeks, with significant difference between the two groups (P <0.05). There was no significant difference in recurrence rate between the two groups . Conclusion Combined use of imiquimod can reduce the initial diagnosis of genital herpes recurrence in the early stages of the disease, but the long-term efficacy is not significant.